Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H13Cl2N5 |
| Molecular Weight | 286.16 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)N=C(N)N=C(N)N1C2=CC=C(Cl)C(Cl)=C2
InChI
InChIKey=FPULLBVUFHTKQQ-UHFFFAOYSA-N
InChI=1S/C11H13Cl2N5/c1-11(2)17-9(14)16-10(15)18(11)6-3-4-7(12)8(13)5-6/h3-5H,1-2H3,(H4,14,15,16,17)
| Molecular Formula | C11H13Cl2N5 |
| Molecular Weight | 286.16 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Chlorproguanil is a biguanide. Chlorproguanil is active against P. falciparum and P. malariae. Chlorproguanil acts by inhibition of dihydrofolate reductase after cytochrome P450-catalysed cyclization. Chlorproguanil combined with dapsone was developing for the treatment of falciparum malaria. The anti-malarial combination chloroproguanil and dapsone has been withdrawn following demonstration of post-treatment haemolytic anaemia in glucose-6-phosphate dehydrogenase (G6PD) deficient patients in a phase III
clinical trial.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Mutations in dhfr in Plasmodium falciparum infections selected by chlorproguanil-dapsone treatment. | 2002-12-15 |
|
| Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. | 2001-10-13 |
|
| Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. | 2000-06 |
|
| Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase. | 1993-09 |
|
| Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs. | 1991-07 |
|
| Pharmacokinetics of Aryldihydro-s-triazines with antifolate activity II: Blood levels and their relevance to antineoplastic activity in rats. | 1978-03 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:44:39 GMT 2025
by
admin
on
Mon Mar 31 21:44:39 GMT 2025
|
| Record UNII |
0624073F45
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
13344-99-5
Created by
admin on Mon Mar 31 21:44:39 GMT 2025 , Edited by admin on Mon Mar 31 21:44:39 GMT 2025
|
PRIMARY | |||
|
159729
Created by
admin on Mon Mar 31 21:44:39 GMT 2025 , Edited by admin on Mon Mar 31 21:44:39 GMT 2025
|
PRIMARY | |||
|
3077
Created by
admin on Mon Mar 31 21:44:39 GMT 2025 , Edited by admin on Mon Mar 31 21:44:39 GMT 2025
|
PRIMARY | |||
|
25889
Created by
admin on Mon Mar 31 21:44:39 GMT 2025 , Edited by admin on Mon Mar 31 21:44:39 GMT 2025
|
PRIMARY | |||
|
0624073F45
Created by
admin on Mon Mar 31 21:44:39 GMT 2025 , Edited by admin on Mon Mar 31 21:44:39 GMT 2025
|
PRIMARY | |||
|
DTXSID00158111
Created by
admin on Mon Mar 31 21:44:39 GMT 2025 , Edited by admin on Mon Mar 31 21:44:39 GMT 2025
|
PRIMARY | |||
|
3877
Created by
admin on Mon Mar 31 21:44:39 GMT 2025 , Edited by admin on Mon Mar 31 21:44:39 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
